A Phase 3 interventional study of Placebo and Vortioxetine in Major Depressive Disorder, sponsored by Takeda. Completed at 47 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-24.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 21st largest by enrollment, is one of 3 that started in 2015, is one of 31 in phase 3, and was the 31st registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 493 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
26 studies in Depressive Disorder, Major by Takeda: 1 open now, 1 under way, 1 of them phase 3. Of 25 finished, 24 (96%) have results posted.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 14th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2015, is one of 16 in phase 3, and was the 21st registered.
Takeda’s Depressive Disorder, Major studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of two fixed doses of vortioxetine (Lu AA21004; 10 or 20 mg/day) after 8 weeks of treatment in patients with major depressive disorder (MDD) in Japan.
This is a randomized, double-blind, placebo-controlled, parallel-group, phase III study to assess the efficacy and safety of 8-week treatment of two fixed doses of Vortioxetine (Lu AA21004; 10 or 20 mg/day) in Japanese participants with major depressive disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The participant has any following current or past history of psychiatric disorder and/or neurological disorder:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo tablets, orally, once daily for up to Week 8
Drug: Placebo
Vortioxetine 10 mg tablets, orally, once daily for up to Week 8
Drug: Vortioxetine
Vortioxetine 10 mg tablets, orally, once daily for up to Week 1 followed by vortioxetine 20 mg tablets, orally, once daily for up to Week 8
Drug: Vortioxetine
Placebo tablets
Vortioxetine tablets
Also known as: Lu AA21004
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Week 8
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.
Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks
MADRS Response at Week 8 (Last Observation Carried Forward (LOCF))
Reported data was percentage of participants who met MADRS response criteria (defined as a ≥50% decrease in the MADRS total score from Baseline) at Week 8 for each group. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.
Time frame: Week 8
MADRS Remission at Week 8 (LOCF)
Reported data was percentage of participants who met MADRS remission criteria (defined as a MADRS total score ≤10) at Week 8 for each group. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.
Time frame: Week 8
Change From Baseline in Hamilton Depression Scale (HAM-D17) Total Score to Week 8 (LOCF)
The HAM-D17 is a clinician-rated scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52 where a higher score indicates a greater depressive state.
Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks
Clinical Global Impressions-Improvement (CGI-I) Score at Week 8 (LOCF)
The CGI-I assesses the participant's state of mental illness improvement. The participant's condition compared to baseline is rated on a seven-point scale (1=very much improved \~ 7=very much worse). Higher scores indicate greater worsening of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms.
Time frame: Week 8
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score to Week 8 (LOCF)
The CGI-S assesses the impression of the participant's current state of mental illness. The current severity of mental illness is rated on a seven-point scale (1=normal, not ill at all \~ 7=most extremely ill) based on a total clinical experience. Higher scores indicate greater severity of mental illness.
Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks
Change From Baseline in Sheehan Disability Scale (SDS) Total Score to Week 8 (LOCF)
The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks
Change From Baseline in Digit Symbol Substitution Test (DSST) Total Score to Week 8 (LOCF)
The DSST is a neuropsychological test to assess cognitive function. Participants are required to copy symbols that are paired with simple geometric shapes or numbers within a specific time for a total possible score of 0 to 133. Higher scores-correct number of symbols reflects greater objective cognitive functioning. An increase in score represents an improvement in an integrated measure of cognitive function.
Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks
Change From Baseline in Perceived Deficits Questionnaire (PDQ-5) Total Score to Week 8 (LOCF)
PDQ-5 is a self-administered 5-item questionnaire to assess cognition function, including subscales of attention/concentration, retrospective memory, prospective memory, and planning/organization. PDQ-5 total score ranges from 0 to 20 with smaller scores indicate greater cognitive function.
Time frame: Baseline (At the start of double-blind treatment period), up to 8 weeks
Participants took part in the study at 64 investigative sites in Japan, from 10 April 2015 to 16 March 2018.
| Milestone | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Started | 164 | 165 | 164 |
| Completed | 149 | 152 | 152 |
| Not completed | 15 | 13 | 12 |
| Withdrew: Randomized but not treated | 1 | 0 | 0 |
| Withdrew: Pretreatment event or adverse event (ae) | 4 | 6 | 7 |
| Withdrew: Major protocol deviation | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Withdrawal of consent | 6 | 4 | 4 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Non compliance with study drug | 1 | 1 | 1 |
| Withdrew: Reason not specified | 0 | 2 | 0 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.
| Scores on a scale | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Week 8 | -12.37 ± 0.714 | -15.03 ± 0.699 | -15.45 ± 0.705 |
Reported data was percentage of participants who met MADRS response criteria (defined as a ≥50% decrease in the MADRS total score from Baseline) at Week 8 for each group. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.
| Percentage of Participants | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| MADRS Response at Week 8 (Last Observation Carried Forward (LOCF)) | 36.6 | 47.9 | 50.6 |
Reported data was percentage of participants who met MADRS remission criteria (defined as a MADRS total score ≤10) at Week 8 for each group. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension). MADRS corresponds to core symptoms of depression, and rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.
| Percentage of Participants | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| MADRS Remission at Week 8 (LOCF) | 21.1 | 32.1 | 30.9 |
The HAM-D17 is a clinician-rated scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52 where a higher score indicates a greater depressive state.
| Scores on a scale | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline in Hamilton Depression Scale (HAM-D17) Total Score to Week 8 (LOCF) | -8.38 ± 0.541 | -10.19 ± 0.524 | -10.17 ± 0.532 |
The CGI-I assesses the participant's state of mental illness improvement. The participant's condition compared to baseline is rated on a seven-point scale (1=very much improved \~ 7=very much worse). Higher scores indicate greater worsening of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms.
| Scores on a scale | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Clinical Global Impressions-Improvement (CGI-I) Score at Week 8 (LOCF) | 2.77 ± 0.085 | 2.42 ± 0.084 | 2.38 ± 0.085 |
The CGI-S assesses the impression of the participant's current state of mental illness. The current severity of mental illness is rated on a seven-point scale (1=normal, not ill at all \~ 7=most extremely ill) based on a total clinical experience. Higher scores indicate greater severity of mental illness.
| Scores on a scale | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score to Week 8 (LOCF) | -1.19 ± 0.0088 | -1.42 ± 0.0087 | -1.48 ± 0.0087 |
The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
| Scores on a scale | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline in Sheehan Disability Scale (SDS) Total Score to Week 8 (LOCF) | -2.85 ± 0.447 | -4.20 ± 0.432 | -4.43 ± 0.440 |
The DSST is a neuropsychological test to assess cognitive function. Participants are required to copy symbols that are paired with simple geometric shapes or numbers within a specific time for a total possible score of 0 to 133. Higher scores-correct number of symbols reflects greater objective cognitive functioning. An increase in score represents an improvement in an integrated measure of cognitive function.
| Scores on a scale | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline in Digit Symbol Substitution Test (DSST) Total Score to Week 8 (LOCF) | 4.92 ± 0.632 | 4.13 ± 0.628 | 4.80 ± 0.629 |
PDQ-5 is a self-administered 5-item questionnaire to assess cognition function, including subscales of attention/concentration, retrospective memory, prospective memory, and planning/organization. PDQ-5 total score ranges from 0 to 20 with smaller scores indicate greater cognitive function.
| Scores on a scale | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Change From Baseline in Perceived Deficits Questionnaire (PDQ-5) Total Score to Week 8 (LOCF) | -1.41 ± 0.234 | -2.28 ± 0.231 | -2.69 ± 0.234 |
Collected over Up to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/161 (0%) | 1/161 (0.6%) | 32/161 (19.9%) |
| Vortioxetine 10 mg | 0/165 (0%) | 1/165 (0.6%) | 54/165 (32.7%) |
| Vortioxetine 20 mg | 2/163 (1.2%) | 3/163 (1.8%) | 51/163 (31.3%) |
| Event | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| NephrolithiasisRenal and urinary disorders | 1/161 | 0/165 | 0/163 |
| Anaesthetic complicationInjury, poisoning and procedural complications | 0/161 | 0/165 | 1/163 |
| Subarachnoid haemorrhageInjury, poisoning and procedural complications | 0/161 | 0/165 | 1/163 |
| Cerebral haemorrhageNervous system disorders | 0/161 | 0/165 | 1/163 |
| Altered state of consciousnessNervous system disorders | 0/161 | 1/165 | 0/163 |
| Event | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 26/161 | 23/165 | 21/163 |
| NauseaGastrointestinal disorders | 1/161 | 21/165 | 25/163 |
| SomnolenceNervous system disorders | 6/161 | 7/165 | 11/163 |
| VomitingGastrointestinal disorders | 0/161 | 9/165 | 6/163 |
Randomized Set, Randomized set was defined as all participants who randomized in this study.
| Age, Continuous(Years) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 39.5 ± 10.47 | 40.0 ± 10.58 | 40.4 ± 11.31 | 40.0 ± 10.78 |
| Sex: Female, Male(Participants) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Female | 72 | 72 | 80 | 224 |
| Male | 92 | 93 | 84 | 269 |
| Race and Ethnicity Not Collected(Participants) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
| Region of Enrollment(Participants) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Japan | 164 | 165 | 164 | 493 |
| Height(Centimeters (cm)) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 166.5 ± 8.51 | 165.2 ± 9.04 | 164.5 ± 7.86 | 165.4 ± 8.51 |
| Weight(Kilograms (kg)) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 62.44 ± 12.218 | 61.97 ± 12.958 | 61.54 ± 12.006 | 61.98 ± 12.382 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 22.44 ± 3.450 | 22.56 ± 3.560 | 22.65 ± 3.594 | 22.55 ± 3.530 |
| Montgomery Åsberg Depression Rating Scale (MADRS) Total Score(Scores on a scale) | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|
| Mean | 30.5 ± 3.87 | 30.8 ± 3.73 | 30.6 ± 3.62 | 30.6 ± 3.73 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2015 to primary completion in Mar 2018, 35 months.
Results were first posted in Jun 2019, 1 year 3 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 35 months is above that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine